Savara Inc.

📍 United States, United States🗓 Founded 2007👥 44 employees💰 Last funded 2015
Pharmaceutical Manufacturing🌐 savarapharma.com
Website LinkedIn
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Australia
1
Frequently asked questions
Who invested in Savara Inc.?
Savara Inc. has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Savara Inc. last raise funding?
The most recent investment in Savara Inc. recorded on gritt.io was in 2015.
When was Savara Inc. founded?
Savara Inc. was founded in 2007.
What industry is Savara Inc. in?
Savara Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Savara Inc. based?
Savara Inc. is headquartered in United States, United States.